Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PGD | P52209 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600329 | 0.86 | PDE4A (0.58) | PDE4APGDTSHROR51E2CYP2C9 | |
| SCHEMBL17984914 | 0.81 | PDE4A (0.41) | PDE4APGDTSHROR51E2CYP2C9 | |
| SCHEMBL26138082 | 0.81 | TSHR (0.56) | PDE4APGDTSHROR51E2CYP2C9 | |
| SCHEMBL17984917 | 0.80 | PDE4A (0.56) | PDE4APGDTSHROR51E2CYP2C9 | |
| L-Threonic Acid SCHEMBL6437643 | 0.78 | — | — | |
| L-Threonic Acid SCHEMBL925622 | 0.78 | — | — | |
| Cadaverine Tartrate SCHEMBL1933180 | 0.78 | TSHR (0.62) | PDE4ATSHROR51E2CYP2C9LMNA | |
| L-Threonic Acid SCHEMBL18614891 | 0.78 | — | — | |
| Cadaverine Tartrate SCHEMBL4214652 | 0.78 | TSHR (0.62) | PDE4ATSHROR51E2CYP2C9LMNA | |
| L-Threonic Acid SCHEMBL120198 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10456481-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2019-10-29 | — | — | US | disclosed |
| US-20180344875-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3049473-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015042711-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE, INC. (CA) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885PGD 1494/4885TSHR 4331/4885 |
| US-20180344875-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885PGD 1494/4885TSHR 4331/4885 |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885PGD 1494/4885TSHR 4331/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885PGD 1494/4885TSHR 4331/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885PGD 1494/4885TSHR 4331/4885 |
| US-10456481-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885PGD 1494/4885TSHR 4331/4885 |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885PGD 1494/4885TSHR 4331/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885PGD 1494/4885TSHR 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.